OVS (OVS) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
23 Dec, 2025Executive summary
Net sales rose 6.2% to €1,631 million, with strong H2 growth and contributions from OVS, Upim, Stefanel, and new brands, despite adverse weather in H1.
Adjusted EBITDA increased by €13.0 million to €195.3 million, absorbing over €4 million in one-off losses and tax reversals.
Cash flow improved by 7% to €68.6 million, with three-year cumulative cash generation near €200 million despite significant investments.
Beauty segment exceeded €100 million in sales, up 20% year-over-year, and maintained double-digit growth.
Proposed dividend of €0.11 per share, up over 50% from the ordinary dividend and 57% from last year, with a €10 million buyback program continuation.
Financial highlights
Gross margin improved to 58.2%, up 91 basis points year-over-year, driven by normalized purchasing conditions.
Net income grew 2.6% to €77.9 million, penalized by higher tax rates due to regulatory changes.
EBIT increased 8.3% to €129.0 million; PBT up 8.0% to €109.5 million.
Q4 net sales rose 5.1% to €455.1 million; Q4 EBITDA impacted by one-off losses and tax reversals.
Net financial debt (adjusted) at €148.3 million, leverage ratio at 0.8x EBITDA.
Outlook and guidance
2025 guidance anticipates continued EBITDA and cash flow growth, with stable or improving gross margin and reduced CapEx by at least €10-15 million.
Expansion in women’s and beauty segments, new launches, and dedicated store openings planned.
Network development and international partnerships expected to drive sales and EBITDA growth.
Cash flow in 2025 to benefit from reduced special investments; ongoing personnel cost increases anticipated.
Macroeconomic uncertainties and increased household costs may slow consumption.
Latest events from OVS
- Q1 sales and margins rose, with strong brand momentum and a positive outlook for 2024.OVS
Q1 20253 Feb 2026 - Sales and margins rose in H1 2024, with strong September momentum and positive outlook.OVS
Q2 202520 Jan 2026 - Q3 2024 delivered double-digit sales and EBITDA growth, with robust outlook and share buybacks.OVS
Q3 202511 Jan 2026 - Sales and EBITDA up, leverage improved, and outlook remains positive for year-end.OVS
Q3 202618 Dec 2025 - Record sales and profit growth in 1H 2025, with strong outlook and Goldenpoint boost.OVS
Q2 202616 Dec 2025 - Q1 sales grew 0.6% to €354.4m; Goldenpoint synergies and Q2 momentum support a positive outlook.OVS
Q1 202614 Nov 2025